HPA Axis Study in Japanese Adults | NCT01407510

Studies
HPA Axis Study in Japanese Adults

NCT01407510

Sponsor

Bayer

Status

Completed

Last Update Posted

Sep 21, 2023Actual

Enrollment

12Actual

Phase

Phase 2

Conditions

Atopic Dermatitis
Eczema

Interventions

Mapracorat

Countries

Japan

Protocol Section

Identification Module Status Module Sponsor/Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms/Interventions Module Outcomes Module Eligibility Module Contacts/Locations Module References Module IPD Sharing Statement Module

Results Section

Participant Flow Module Baseline Characteristics Module Outcome Measures Module Adverse Events Module More Info Module

Annotation Section

Annotation Module

Document Section

Large Document Module

Derived Section

Miscellaneous Info Module Condition Browse Module Intervention Browse Module

Protocol Section

Identification Module

NCT ID

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Version Holder

ID	Type	Description	Link
1403460	Other Identifier	Company Internal

Status Module

Record Verification Date

Sep 2023

Overall Recruitment Status or Expanded Access Status

Completed

Last Known Status

Not provided

Delayed Posting

Not provided

Why Stopped

Not provided

Expanded Access Info

Start Date

May 9, 2011Actual

Primary Completion Date

Sep 16, 2011Actual

Completion Date

Apr 15, 2012Actual

First Submitted Date

Aug 1, 2011

First Submission Date that Met QC Criteria

Aug 1, 2011

First Posted Date

Aug 2, 2011Estimated

Results Waived

Not provided

Results First Submitted Date

Not provided

Results First Submitted that Met QC Criteria

Not provided

Results First Posted Date

Not provided

Certification/Extension (aka Delayed Results) First Submitted Date

Not provided

Certification/Extension First Submitted that Passed QC Review

Not provided

Certification/Extension First Posted Date

Not provided

Last Update Submitted Date

Sep 18, 2023

Last Update Posted Date

Sep 21, 2023Actual

Oversight Module

Has Data Monitoring Committee (DMC)

Is FDA Regulated Drug

Not provided

Is FDA Regulated Device

Not provided

Is Unapproved Device

Not provided

Pediatric Postmarket Surveillance of a Device Product

Not provided

Product Exported from US

Not provided

FDAAA801 Violation

Not provided

Description Module

Brief Summary

A multicenter, open-label study to evaluate the adrenal suppression potential of Mapracorat 0.1% ointment in Japanese adults with atopic dermatitis.

Detailed Description

Assessment of the adrenal suppression potential, safety, efficacy and pharmacokinetics of Mapracorat 0.1% ointment in Japanese adults with atopic dermatitis.

Design Module

Study Type

Interventional

Number of References to an Expanded Access Study

Not provided

Expanded Access Types

Not provided

Patient Registry

Not provided

Target Follow-Up Duration

Not provided

Phases

Phase 2

Interventional Study Design

Allocation

Biospecimen

No data available

No data is available for this block.

Enrollment

12Actual

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Arm 1	Experimental		Drug: Mapracorat

Interventions

Name	Type	Description	Arm Group Labels	Other Names
Mapracorat	Drug	Application of the investigational product on the affected skin areas	Arm 1

Measure	Description	Time Frame
number of subjects with adrenal suppression

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

Signed written informed consent
Male or female subject aged >= 20 years
Diagnosis of atopic dermatitis according to the Hanifin and Rajka criteria
Investigator's Global Assessment (IGA) score of 3 (moderate) to 4 (severe) at baseline
Normal ACTH response before start of treatment

Exclusion Criteria:

Pregnancy or lactation
Clinically relevant disease, which could interfere with the study conduct or the evaluation and interpretation of the study results
Concomitant medical or dermatological disorder(s), which could interfere with the investigator's ability to evaluate the subject's response to the investigational product
Clinically manifest immunosuppressive disorder or known history of malignant disease

Accepts Healthy Volunteers

Sex

All

Sex/Gender Based

Not provided

Sex/Gender Description

Not provided

Minimum Age

20 Years

Maximum Age

Not provided

Standard Ages

AdultOlder Adult

Study Population

Not provided

Sampling Method

Not provided

Contacts/Locations Module

Central Contacts

Not provided

Overall Officials

Name	Affiliation	Role
Bayer Study Director	Bayer	Study Director

Locations

Facility	Status	City	State	ZIP	Country	Contacts
Kawaguchi Kogyo General Hospital		Saitama			Japan
Clinical Research Hospital Tokyo

Condition Browse Module

MeSH Terms

ID	Term
D003876	Dermatitis, Atopic
D004485	Eczema

Ancestor Terms

ID	Term
D012873	Skin Diseases, Genetic
D030342	Genetic Diseases, Inborn
D009358	Congenital, Hereditary, and Neonatal Diseases and Abnormalities
D003872	Dermatitis

Browse Leaves

Not provided

Browse Branches

Not provided

Intervention Browse Module

MeSH Terms

ID	Term
C546413	R-1,1,1-trifluoro-4-(5-fluoro-2,3-dihydrobenzofuran-7-yl)-4-methyl-2-(((2-methyl-5-quinolyl)amino)methyl)pentan-2-ol

Ancestor Terms

Not provided

Browse Leaves

Not provided

Browse Branches

Not provided